“The FDA has issued a nationwide recall of lisdexamfetamine capsules.”
That sentence in Newsweek magazine should have triggered alerts, guidance, and coordinated response. Instead, the silence from pediatric leadership has been deafening. Newsweek turned to the FDA and the American Academy of Family Physicians. Where are the leadership of the American Academy of Pediatrics (AAP) and the Society for Developmental and Behavioral Pediatrics? Silent. Why?
The recall that should have sparked action
In November 2025, the FDA classified a nationwide recall of lisdexamfetamine dimesylate capsules (commonly known as Vyvanse) as a Class II recall. This means the product may cause temporary or medically reversible adverse health consequences. The manufacturer, Sun Pharmaceutical Industries, initiated the recall. The FDA confirmed the risk.
Real physician voices, twice a week
Free, and one click to unsubscribe.
This isn’t a fringe medication. Lisdexamfetamine is a first-line treatment for ADHD, prescribed to millions of children and adults. It anchors school routines, family stability, and clinical care. A recall of this magnitude should have triggered immediate alerts from the American Academy of Pediatrics (AAP) and the Society for Developmental and Behavioral Pediatrics (SDBP).
But they said nothing.
Clinical fallout: risk without guidance
Families managing ADHD now face:
- Pharmacy confusion
- Abrupt medication changes
- Uncertainty about safety and supply
- Silence from the very institutions meant to guide them
Clinicians must now navigate risk without a compass. They must explain a recall without institutional backing. They must reassure families without data, context, or coordinated messaging. This isn’t just a missed opportunity. It’s a dereliction of duty.
I was targeted; I resisted
I remember the pitch while I was Director of Research at the Arizona Child Study Center. A pharmaceutical rep (proud of her basketball grit) spoke glowingly about Adderall. She knew the game. She knew Dianna Taurasi from UCONN. She also knew how to sell.
When Vyvanse entered the market, she flipped the script. Suddenly, Adderall became unreliable. She lambasted its pharmacokinetics and pushed Vyvanse as the superior solution. She didn’t cite data. She performed allegiance.
I had already seen Adderall’s variability firsthand. I knew its duration of action could be erratic. But I also knew the sales pitch wasn’t about science. It was about market share.
I resisted. I didn’t take the dinners. I didn’t accept the gifts. I didn’t let Big Pharma choreograph my prescribing habits.
Many of my colleagues did. They accepted the meals, the branded pens, the conference perks. They let the marketing shape their clinical decisions. Now, when a nationwide recall hits, they stay silent. They don’t warn families. They don’t challenge the manufacturers. They don’t speak, because they’ve already been bought.
The AAFP still holds the line. As for the AAP and SDBP, their continued silence raises difficult questions about the potential influence of industry funding, leaving families to navigate these risks alone.
The broader collapse: measles, misinformation, and institutional retreat
This recall arrives amid a broader collapse in pediatric public health. The CDC recently revised its vaccine safety language, stating that “the claim ‘vaccines do not cause autism’ is not evidence-based because studies have not ruled out the possibility.” This rhetorical retreat mirrors the same institutional cowardice.
Meanwhile, the U.S. is on the brink of losing its measles elimination status, just as Canada did last week. The outbreak that began in Texas in January shows no signs of slowing. If it continues into January 2026, measles will be reclassified as endemic.
This year alone:
- Over 1,700 measles cases
- 45 outbreaks
- 211 hospitalizations, including 100 children under age five
- Three deaths
Whooping cough cases are also surging. This isn’t just a public health failure. It’s a collapse of coordinated care, fueled by rhetorical sabotage and institutional retreat.
The cost of silence
As a developmental pediatrician, I’ve watched families unravel under the weight of uncertainty. As a historian, I’ve documented what happens when institutions retreat from their mission. When pediatric leadership refuses to speak, others fill the void, with misinformation, fear, and opportunism.
We cannot afford that void. Not now. Not with ADHD care under siege. Not with measles returning. Not with trust in medicine hanging by a thread.
Ronald L. Lindsay is a retired developmental-behavioral pediatrician whose career spanned military medicine, academic leadership, and national advocacy for dignity-centered neurodevelopmental care. His NIH-funded work with the RUPP Autism Network helped define evidence-based approaches to autism and related developmental disorders.
He directed the LEND Program at The Ohio State University and founded JBLM CARES, a $10 million autism resource center for military families. His writing spans clinical scholarship and long-form fiction. He is the author of The Mercy Directive and the six-novel Cassandra series, a completed political and medical fiction saga tracing the rise of the Cassandra system from its origins to its national and international legacy. His forthcoming memoir, The Quiet Architect, examines how conscience and structure collide in modern medicine.
He shares updates on LinkedIn.
